Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
Bullboard Posts
User Avatar Image
(1507)
•••
Comment by wildbird1on Oct 01, 2019 2:42pm
154 Views
Post# 30183334

RE:RE:RE:RE:RE:RE:RE:ALWAYS SEEMS LIKE NO ONE KNOWS ABOUT SZLS

RE:RE:RE:RE:RE:RE:RE:ALWAYS SEEMS LIKE NO ONE KNOWS ABOUT SZLSAgree... In the link below...

https://stagezerolifescience.com/uploads/1/4/5/4/14548558/so-2101_r01_colonsentry_scientific_overview.pdf

Page 2 ...Last phrase
  " Although colonsentry itself is not a screening test, the colonsentry results can help physician and patients decide on a case by case basis whether colonoscopy or other screening method is warranted".

Meaning:
ColonSentry can predict the chance of having cancer before the cancer symptoms appear on a colonoscopy.
That is what make Colonsentry so valuable, and it does cost much less than the very expensive colonoscopy.


frewil11 wrote: The science will tell you if you are at risk of getting a certain cancer and how high of a risk you are , if you are high risk you will get tested more often so you can catch it as early as possible , this is how I see it. 


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities